Session Title: LASIK
Session Date/Time: Wednesday 09/10/2013 | 08:00-10:30
Paper Time: 08:42
Venue: Auditorium (First Floor)
First Author: : G.Pamel USA
Co Author(s): : A. Kanellopoulos G. Asimellis
Purpose:
The evaluation of safety, efficacy, ergonomy, and refractive and keratometric stability in high myopia LASIK procedures utilizing a novel femtosecond and excimer laser surgery platform.
Setting:
Laservision.gr Eye Institute, Athens, Greece
Methods:
116 eyes in consecutive cases of high myopic LASIK procedure with the Alcon-WaveLight FS200 femtosecond and EX500 excimer lasers were evaluated pre- and post- operatively for the following parameters: Refractive Error (RE), best Corrected Distance Visual Acuity (CDVA), Uncorrected Distance Visual Acuity (UDVA), spherical equivalent correction, keratometry (with Placido topography and Scheimpflug tomography), and refractive astigmatism. Average follow-up time was 6.2 months (range 3 -12).
Results:
Post-operative average refractive error (RE) was -0.37 diopters (D), -0.43 D, and -0.25 D for the 3-, 6-, and 12-month period, compared to pre-operative average RE of -7.67 ± 1.55 D (range -12.625 to -6.00 D). Eyes within 1.0 D defocus equivalent, were 94.0%, 96.3%, and 100%, during the 3-, 6-, and 12--month visit, respectively.
Post operative refractive astigmatism was -0.21, -0.21, -0.13 D, for the 3-, 6-, and12-month period, compared to pre-operative average of -1.07 ± 1.91 D (range -4.25 to 0).
The proportion of the eyes with post-operative astigmatism within 0.25 D was 85.3%, 81.50% and 100%, for the 3-, 6-, and 12-month visit, respectively. Keratometric stability was within 0.22 D after the 12-month visit.
There was no epithelial ingrowth or diffuse lamellar keratitis (DLK) in any case.
Conclusions:
clinical outcomes with this technique and technology appear to be very promising in high level uncorrected visual rehabilitation of high myopia. There was very small regression potential in the sample evaluated
Financial Interest:
... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
Please wait while information is loading.